MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN
文献类型：期刊论文
| 作者 | Wang, Huimin1; Ma, Zhongliang1; Liu, Xiaomin1; Zhang, Caiyan1; Hu, Yanping2; Ding, Lei1; Qi, Pengfei1; Wang, Ju1,3; Lu, Shengdi4; Li, Yanli1 |
| 刊名 | BIOMEDICINE & PHARMACOTHERAPY
 |
| 出版日期 | 2019-03-01 |
| 卷号 | 111页码:1103-1111 |
| 关键词 | miR-183-5p Non-small cell lung cancer PTEN Tumorigenesis |
| ISSN号 | 0753-3322 |
| DOI | 10.1016/j.biopha.2018.12.115 |
| 通讯作者 | Lu, Shengdi(lushendi0828@163.com) ; Li, Yanli(liyanli@shu.edu.cn) |
| 英文摘要 | Lung cancer is the leading cause in all cancer deaths. A low survival rate and high recurrence rate of lung cancer make the endeavor to identify new, more effective therapies a primary goal. MicroRNAs (miRNAs) are regarded as regulators of tumorigenesis and it is known that miR-183-5p is significantly upregulated in non-small cell lung cancer (NSCLC), suggesting it has an oncogenic function in lung cancer. In this study, we found that miR-183-5p could promote lung carcinogenesis by directly targeting phosphatase tensin (PTEN). Further experiments indicated that miR-183-5p could suppress p53 and activate AKT signaling through phosphorylation. Moreover, our data indicated that miR-183-5p promoted tumor metastasis and tumor growth in vivo. Collectively, these results showed that miR-183-5p is required for NSCLC development through the suppressing PTEN, and might be a promising target in the diagnosis and treatment of lung cancer in the future. |
| WOS关键词 | PROLIFERATION ; BIOMARKER ; PROMOTES ; MIRNAS ; NSCLC ; EXPRESSION ; APOPTOSIS ; CLUSTER ; TARGET ; CYCLE |
| 资助项目 | Training Program of the Major Research Plan of the National Natural Science Foundation of China[91543123] ; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences[SIMM1601KF-12] |
| WOS研究方向 | Research & Experimental Medicine ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000458737800118 |
| 出版者 | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/290513]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Lu, Shengdi; Li, Yanli |
| 作者单位 | 1.Shanghai Univ, Sch Life Sci, Lab Noncoding RNA & Canc, Shanghai 200444, Peoples R China 2.China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Jiangsu, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 4.Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Huimin,Ma, Zhongliang,Liu, Xiaomin,et al. MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN[J]. BIOMEDICINE & PHARMACOTHERAPY,2019,111:1103-1111. |
| APA | Wang, Huimin.,Ma, Zhongliang.,Liu, Xiaomin.,Zhang, Caiyan.,Hu, Yanping.,...&Li, Yanli.(2019).MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN.BIOMEDICINE & PHARMACOTHERAPY,111,1103-1111. |
| MLA | Wang, Huimin,et al."MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN".BIOMEDICINE & PHARMACOTHERAPY 111(2019):1103-1111. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。